文献速递免疫规划传染病防控与疫情报告

Δcps1减毒活疫苗预防犬实验性球孢子菌病的耐受性与效力研究

Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis.
PubMed 文献 · Vaccine · 2021-10-23

本研究在犬攻毒模型中测试Δcps1减毒活疫苗预防肺球孢子菌病的耐受性与效力。接种部位反应为一过性,无全身效应;七处接种部位中六处及所有引流淋巴结在接种后无菌。攻毒后,初免加加强组犬肺部真菌负荷(P=0.0003)和综合疾病评分(P=0.0002)显著低于未接种组;单剂接种组真菌负荷介于两剂组与未接种组之间,但疾病评分与未接种组无显著差异(P=0.675)。

要点

  • Δcps1疫苗在犬中耐受良好,接种部位反应为一过性且无全身效应。
  • 初免加加强接种可显著降低攻毒后肺部真菌负荷和综合疾病评分。
  • 单剂接种的保护效果介于两剂与未接种之间,疾病评分无显著改善。

核心结论

  • Δcps1减毒活疫苗在犬中耐受良好,初免加加强接种可提供高水平保护。
  • 结果支持推进Δcps1疫苗的兽用许可并继续开发人用疫苗。

研究设计与样本

  • 在犬攻毒模型中测试Δcps1减毒活疫苗的耐受性与预防肺球孢子菌病的效力。
  • 以Coccidioides posadasii Silveira株关节孢子经肺感染进行攻毒。
  • 比较初免加加强、单剂接种与未接种犬的肺部真菌负荷和综合疾病评分。

主要发现

  • 接种部位反应为一过性,未观察到全身效应。
  • 七处接种部位中六处及所有引流淋巴结在接种后无菌。
  • 初免加加强组肺部真菌负荷显著低于未接种组(P=0.0003)。
  • 初免加加强组综合疾病评分显著低于未接种组(P=0.0002)。
  • 单剂接种组真菌负荷介于两剂组与未接种组之间,疾病评分与未接种组无显著差异(P=0.675)。

临床怎么用

  • 原文为犬攻毒模型研究,尚未提供临床接种方案或人用剂量推荐。
  • 结果提示初免加加强两剂程序可能优于单剂,但需进一步临床研究确认。

局限性

  • 研究为实验性犬攻毒模型,结果外推至自然暴露或人类需谨慎。
  • 单剂接种组样本量有限,疾病评分未显示显著保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coccidioidomycosis is a significant health problem of dogs and humans in endemic regions, especially California and Arizona in the U.S. Both species would greatly benefit from a vaccine to prevent this disease. A live avirulent vaccine candidate, Δcps1, was tested for tolerability and efficacy to prevent pulmonary coccidioidomycosis in a canine challenge model. Vaccine injection-site reactions were transient and there were no systemic effects observed. Six of seven vaccine sites tested and all draining lymph nodes were sterile post-vaccination. Following infection with Coccidioides posadasii, strain Silveira, arthroconidia into the lungs, dogs given primary and booster vaccinations had significantly reduced lung fungal burdens (P = 0.0003) and composite disease scores (P = 0.0002) compared to unvaccinated dogs. Dogs vaccinated once had fungal burdens intermediate between those given two doses or none, but disease scores were not significantly different from unvaccinated (P = 0.675). Δcps1 was well-tolerated in the dogs and it afforded a high level of protection when given as prime and boost. These results drive the Δcps1 vaccine toward a licensed veterinary vaccine and support continued development of this vaccine to prevent coccidioidomycosis in humans.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shubitz LF, Robb EJ, Powell DA, et al. Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis. Vaccine. 2021. PMID: 34696935. doi:10.1016/j.vaccine.2021.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。